Ola Landgren
Impact in
- Hematology top 0.01%
- Multiple Myeloma Research and Treatments
- Genetics top 0.05%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Papers in
- Hematology 427
- Multiple Myeloma Research and Treatments 395
- Genetics 165
- Chronic Lymphocytic Leukemia Research 113
- Myeloproliferative Neoplasms: Diagnosis and Treatment 50
- Co-authors
- Sigurdur Yngvi Kristinsson (122 shared papers)Magnus Björkholm (117 shared papers)Lynn R. Goldin (62 shared papers)Ingemar Turesson (60 shared papers)Ruth Pfieffer (43 shared papers)S.Vincent Rajkumar (22 shared papers)Eric A. Engels (30 shared papers)Gloria Gridley (26 shared papers)
- Journals
- Blood (150 papers)Haematologica (24 papers)Leukemia (23 papers)Blood Cancer Journal (21 papers)Journal of Clinical Oncology (18 papers)
- Partner nations
- United StatesSwedenIceland
In The Last Decade
Ola Landgren
607 papers receiving 34.3k citations
Ola Landgren's Hit Papers
Peers
Comparison fields: 5 of 159
- Hematology 21.7k
- Genetics 7.2k
- Oncology 10.7k
- Pathology and Forensic Medicine 3.9k
- Molecular Biology 12.6k
Countries citing papers authored by Ola Landgren
This map shows the geographic impact of Ola Landgren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Landgren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Landgren more than expected).
Fields of papers citing papers by Ola Landgren
This network shows the impact of papers produced by Ola Landgren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Landgren. The network helps show where Ola Landgren may publish in the future.
Co-authors
The 25 scholars most cited alongside Ola Landgren, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 628 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma Hit paper breakdown → | 2014 | 3585 |
| 2 | International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Hit paper breakdown → | 2016 | 2367 |
| 3 | Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study Hit paper breakdown → | 2009 | 882 |
| 4 | Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management Hit paper breakdown → | 2010 | 660 |
| 5 | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study Hit paper breakdown → | 2011 | 652 |
| 6 | Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report Hit paper breakdown → | 2015 | 641 |
| 7 | 2014 | 398 | |
| 8 | 2008 | 385 | |
| 9 | Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study Hit paper breakdown → | 2020 | 344 |
| 10 | 2009 | 334 | |
| 11 | 2010 | 330 | |
| 12 | 2014 | 330 | |
| 13 | GPRC5D-Targeted CAR T Cells for Myeloma Hit paper breakdown → | 2022 | 326 |
| 14 | 2009 | 288 | |
| 15 | 2012 | 285 | |
| 16 | 2005 | 268 | |
| 17 | 2007 | 264 | |
| 18 | 2015 | 264 | |
| 19 | 2007 | 263 | |
| 20 | 2008 | 259 |
About Ola Landgren
Ola Landgren is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Molecular Biology, having authored 628 papers that have together received 35.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (395 papers), Protein Degradation and Inhibitors (136 papers), Chronic Lymphocytic Leukemia Research (113 papers), Lymphoma Diagnosis and Treatment (71 papers), Peptidase Inhibition and Analysis (56 papers), Cancer Treatment and Pharmacology (53 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (50 papers) and Amyloidosis: Diagnosis, Treatment, Outcomes (44 papers). The work is most often cited by research in Hematology (21.7k citations), Genetics (7.2k citations), Oncology (10.7k citations), Pathology and Forensic Medicine (3.9k citations) and Molecular Biology (12.6k citations). Ola Landgren has collaborated with scholars based in United States, Sweden and Iceland. Frequent co-authors include Sigurdur Yngvi Kristinsson, Magnus Björkholm, Lynn R. Goldin, Ingemar Turesson, Ruth Pfieffer, S.Vincent Rajkumar, Eric A. Engels, Gloria Gridley, Neha Korde and Malin L. Hultcrantz. Their work appears in journals such as Blood, Haematologica, Leukemia, Blood Cancer Journal and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.